Last update 01 Nov 2024

ARGO BIOPHARMA AUSTRALIA PTY LTD

Private Company|
2022|
Australia

Overview

Basic Info

Introduction
Argo Biopharma specializes in siRNA drug discovery and development. Their industry-leading siRNA platform technology, RADS (RNA molecules with superior Activity, Durability, and Safety), is the cornerstone of their innovative approach. Based on this platform, drugs can achieve the expected one injection per year in clinical practice in some indications.

Tags

Congenital Disorders
Immune System Diseases
Digestive System Disorders
siRNA

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Infectious Diseases1
Immune System Diseases1
Top 5 Drug TypeCount
siRNA2
Top 5 TargetCount
HBV RNA1

Related

2
Drugs associated with ARGO BIOPHARMA AUSTRALIA PTY LTD
BW-20507
Target
HBV RNA
Mechanism
HBV RNA inhibitors
Active Org.
ARGO BIOPHARMA AUSTRALIA PTY LTD [+1]
Originator Org.
Hangzhou Bolin Pharmaceutical Technology Co., Ltd.
Active Indication
Hepatitis B, Chronic
Inactive Indication-
Drug Highest PhasePhase 1/2
First Approval Ctry. / Loc.-
First Approval Date-
BW-20805
Target-
Mechanism-
Active Org.
Hangzhou Bolin Pharmaceutical Technology Co., Ltd. [+1]
Originator Org.
Hangzhou Bolin Pharmaceutical Technology Co., Ltd.
Active Indication
Hereditary Angioedema
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
7
Clinical Trials associated with ARGO BIOPHARMA AUSTRALIA PTY LTD
ACTRN12623001200673 / RecruitingPhase 1
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-20829 in subjects with elevated lipoprotein(a)
ACTRN12623000689673 / RecruitingPhase 1
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-20805 in Healthy Subjects
ACTRN12623000709640 / RecruitingPhase 1/2
A Phase 1/2 Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BW-20507 in Healthy Subjects
100 Clinical Results associated with ARGO BIOPHARMA AUSTRALIA PTY LTD
Login to view more data
0 Patents (Medical) associated with ARGO BIOPHARMA AUSTRALIA PTY LTD
Login to view more data
100 Deals associated with ARGO BIOPHARMA AUSTRALIA PTY LTD
Login to view more data
100 Translational Medicine associated with ARGO BIOPHARMA AUSTRALIA PTY LTD
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 30 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1 Clinical
1
1
Phase 2 Clinical
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
BW-20507
 ( HBV RNA )		Hepatitis B, Chronic
More
Phase 2 Clinical
BW-20805
Hereditary Angioedema
More
Phase 1
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free